A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

NCT00171145 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

445

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder Syndrome

Interventions

DRUG: Darifenacin
DRUG: Placebo

Sponsor

Novartis